AES Corporation (AES) is heading into its next report on rising estimates and good valuations.

Company Description

AES provides energy to 29 countries with energy through generation and distribution. The company has diversified portfolio of thermal and renewable fuel sources.

EPS Rises

On Aug 7 the company announced quarterly earnings per share of 28 cents, 3 cents higher than last year and 8 cents higher than the Zacks Consensus Estimate.

All types of cash flow increased dramatically, including a $181 million jump in Consolidated Cash Flow, to $495 million.

Raising Guidance

During the same release the company raised full-year EPS guidance to between $1.05 and $1.10. The bottom and top end of the range rose 8 cents and 3 cents, respectively.

Solid Growth

Analyst estimates are coming in near the middle of the AES's forecasts, which would yield earnings growth of 9% this year. The Zacks Consensus Estimate is now $1.23,

...

Results from Arena’s (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups is at least 5% and the difference is statistically significant, or (2) the proportion of subjects who lose ...

Ardea Biosciences' Gout Drug Shows Promising Results  Positive results from phase II a and phase I trialsRDEA594 is Ardea Biosciences' (RDEA) lead drug candidate for the treatment of gout. The company recently announced positive interim results from an ongoing phase IIa, proof-of-concept study of RDEA594 for the treatment of hyperuricemia and gout, as well as additional positive results from completed phase I studies of RDEA594 in normal, healthy volunteers.In late April 2009, the company initiated a placebo- and active-controlled, proof-of-concept study of RDEA594 in gout patients with hyperuricemia (uric acid = 8 mg/dL). This study is now fully enrolled and the majority of the 20 patients have completed the first week of dosing. Patients received RDEA594 200 mg once daily (QD) for the first week, followed by 400 ...

AuthenTec, Inc. stock was upgraded from “Outperform” to “Strong Buy” by Raymond James Financial on Thursday (June 12th). The announcement fueled a rapid appreciation of 12.3 percent for the day.

AuthenTec itself has been growing by leaps and bounds, seeing a 67 percent revenue increase in the first quarter of 2008. In a recent conference call held to discuss the quarter ended March 31st, the company expressed the belief that 2008 revenues will only continue to grow. It is estimated that earnings for the second quarter will total more than $17.2 million, as a result of large-volume shipments of the company’s “AES 2810″ PC fingerprint-authentication product. It has also been reported that Intel’s Montevina laptops will come equipped with the AES 2810 sensors, to begin shipping in the second half of 2008.

In addition, AuthenTec has announced its intent to step up research and development efforts in a play for an

...